Post-Grant Review: The Good, the Bad and the Ugly for Biotechnology Companies

This paper summarizes the Post-Grant Review process, one of the many interesting aspects of patent reform brought about by the enactment of the America Invents Act, and the effect it may have on how Biotechnology companies conduct business and manage their intellectual property. Full details at the Journal of Commercial Biotechnology

Comments are closed.

Biotechblog